AI
ABOS icon

Atom Investors’s Acumen Pharmaceuticals ABOS Stock Holding History

Atom Investors’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-33,678
Closed -$57.9K – 490
2024
Q4 		$57.9K Buy
+33,678
New +$81.1K 0.01% 467
2023
Q2 		– Sell
-62,952
Closed -$256K – 285
2023
Q1 		$256K Buy
62,952
+511
+0.8% +$2.67K 0.14% 171
2022
Q4 		$337K Buy
+62,441
New +$420K 0.17% 123

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return

Atom Investors's ABOS Position: Q1 2025 in Review

Atom Investors sold out of Acumen Pharmaceuticals (ABOS) in Q1 2025, closing a stake of 33,678 shares — an estimated $57.9K sold.

Atom Investors first reported a position in ABOS in Q4 2022 and held it in 3 quarters. The position peaked at $337K in Q4 2022. 81 funds tracked by Wall St. Rank hold ABOS as of Q1 2025.

  • Atom Investors reported no remaining Acumen Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Atom Investors sold 33,678 Acumen Pharmaceuticals shares in Q1 2025, an estimated $57.9K.
  • Atom Investors first reported a position in Acumen Pharmaceuticals in Q4 2022 and held it in 3 quarters.
  • Atom Investors's Acumen Pharmaceuticals position peaked at $337K in Q4 2022.
  • 81 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2025.

Based on Atom Investors's 13F filing for Q1 2025, filed 15 May 2025.